Cell-based assays utilize living cells to measure biological activities. They offer physiological relevance, dynamic responses, versatility, and high-throughput capability. These assays find applications in drug discovery, toxicity testing, disease modeling, functional genomics, signal transduction studies, and diagnostics. They aid in identifying drug targets, evaluating drug efficacy and toxicity, understanding disease mechanisms, studying gene and protein function, and diagnosing diseases. Cell-based assays are valuable tools for understanding complex biological systems and developing new treatments.
Access Full Report at https://www.databridgemarketresearch.com/reports/global-cell-based-assays-market
Data Bridge Market Research analyses that the Global Cell Based Assays Market is valued at USD 18.9 billion in 2021 and is expected to reach USD 32.96 billion by 2029, registering a CAGR of 7.2% during the forecast period of 2022 to 2029. Precision medicine focuses on delivering the right treatment to the right patient at the right time. Cell-based assays enable the identification and characterization of specific biomarkers and molecular targets associated with diseases, facilitating the development of precise diagnostic and therapeutic approaches which drive the market’s growth.
Key Findings of the Study
Advancements in cellular technologies is expected to drive the market's growth rate
The physiological relevance of cell-based assays has been enhanced by ongoing progress in cell culture techniques, 3D cell culture models, and organ-on-a-chip technologies. These advancements have resulted in improved predictive capabilities and have led to a greater adoption of cell-based assays in research and development activities. The increased physiological fidelity provided by these advancements has made cell-based assays more valuable tools for studying biological processes and evaluating the effectiveness of potential treatments.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Cell Viability Assay, Cytotoxicity Assay, Cell Death Assay, Cell Proliferation Assay and Others), Product and Services (Consumables, Services, Instruments and Software), Technology (Flow Cytometry, High Throughput Screening, High Content Screening and Label Free Detection), Application (Drug Discovery, Basic Research, Others), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutions, Government Organizations, Others), Distribution Channel (Direct, Indirect)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Danaher (U.S.), Thermo Fisher Scientific (U.S.), Merck KGaA (Germany), BD (U.S.), GE (U.S.), PerkinElmer, Inc. (U.S.), Promega Corporation (U.S.), Charles River Laboratories (U.S.), Cell Signaling Technology, Inc. (U.S.), Lonza (Switzerland), BioAgilytix Labs (U.S.), Cisbio (U.S.), Reaction Biology (U.S.), Lebermuth, Inc. (U.S.), Eurofins DiscoverX Products (U.S.), and AAT Bioquest, Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The cell based assays market is segmented on the basis of type, product and services, technology, application, end user, and distribution channel.
- On the basis of type, the cell based assays market is segmented into cell viability assay, cytotoxicity assay, cell death assay, cell proliferation assay, and others. In 2022, the cell viability assay segment is expected to dominate the global surgical optical operating microscope market during the forecast period 2022 to 2029 as cell viability assays are a critical component of cell-based assays as they assess the viability and health of cells in a sample.
In 2022, the cell viability assay segment is dominating the type segment of the global cell based assays market
In 2022, the cell viability assay segment is dominating the market cell viability assays have been extensively studied and optimized over time, leading to the development of standardized methods and protocols. This established methodology simplifies their implementation in research and screening processes, making them a preferred choice for many researchers and pharmaceutical companies.
- On the basis of product and services, the cell based assays market is segmented into consumables, services, instruments and software. In 2022, consumables segment is expected to dominate the global surgical optical operating microscope market during the forecast period 2022 to 2029 as the increasing adoption of cell-based assays, advancements in assay technologies, demand for reliable and high-quality assay materials, and the growing need for screening and drug discovery applications
- On the basis of technology, global cell based assays market is segmented into flow cytometry, high throughput screening, high content screening and label free detection. In 2022, high throughput screening segment is expected to dominate the global cell based assay market CAGR of 9.6% in the forecast period of 2022 to 20229 as t allows for rapid analysis of a large number of cells, making it suitable for high-throughput screening and analysis.
- On the basis of application, the cell based assays market is segmented into drug discovery, basic research, and others. The drug discovery segment dominates the application segment during the forecast period 2022 to 2029 as they will help identify promising drugs by assessing their activity, potency, selectivity, and toxicity profiles in relevant cell models.
In 2022, the drug discovery segment is dominating the application of the global cell based assays market
In 2022, the drug discovery segment is dominating the application segment of the global cell based assays market during the forecast period 2022 to 2029 due to the critical role cell-based assays play in identifying and developing potential drug candidates. These assays provide valuable insights into compound efficacy, safety, and toxicity profiles in relevant cellular models.
- On the basis of end user, the cell based assays market is segmented into pharmaceutical and biotechnology companies, contract research organizations, academic and research institutions, government organizations and others. The pharmaceutical and biotechnology companies segment dominates the end user segment during the forecast period 2022 to 2029 as these companies work across diverse therapeutic areas, including oncology, neurology, infectious diseases, cardiovascular diseases, and more.
- On the basis of distribution channel, the cell based assays market is segmented into direct and indirect. The direct segment dominates the end user segment during the forecast period 2022 to 2029 they provide direct measurement of a specific cellular response or target without the need for additional steps or amplification processes
Major Players
Data Bridge Market Research recognizes the following companies as the major cell based assays market players in cell based assays market are Danaher (U.S.), Thermo Fisher Scientific (U.S.), Merck KGaA (Germany), BD (U.S.), GE (U.S.), PerkinElmer, Inc. (U.S.)
Market Developments
- In December 2021, Thermo Fisher Scientific's acquisition of PPD aims to strengthen its clinical research services for the biopharma and biotech industries. The acquisition enables Thermo Fisher Scientific to expand its capabilities and offerings in clinical research, including clinical trial design, management, and execution.
- In March 2020, Danaher's acquisition of General Electric's Life Sciences Division, which has been renamed Cytiva, is aimed at bolstering its portfolio of Life Sciences products and services. The acquisition allows Danaher to expand its offerings in the Life Sciences sector by incorporating Cytiva's expertise and resources.
- In August 2022, LifeNet Health LifeSciences has introduced a range of Cell-Based Assay Services, which encompass cytotoxicity screening, biocompatibility assays, and other related offerings.
- In May 2022, The introduction of the Aquios STEM system by Beckman Coulter Life Sciences brings forth a novel solution for stem cell analysis. This innovative technology aims to expedite the analysis process by reducing turnaround time and minimizing manual labor and potential errors.
Regional Analysis
Geographically, the countries covered in the cell based assays market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in cell based assays market during the forecast period 2022 - 2029
In 2022, North America dominated the cell based assays market due to significant increase in awareness regarding the importance of cell-based assays in drug discovery. This, coupled with the rapid growth in the development and utilization of these assays, has contributed to their fast-paced growth within the region. Researchers and pharmaceutical companies recognize the benefits of using cell-based assays for understanding cellular mechanisms, predicting drug responses, and evaluating compound efficacy, leading to increased adoption and investment in these assays for drug discovery purposes.
Asia-Pacific is estimated to be the fastest growing region in cell based assays market the forecast period 2022 - 2029
Asia-Pacific is expected to grow during the forecast period due to the adoption of strategic approaches, including collaborations, for the development of drug candidates. Furthermore, the government has increased its investments in research and development, creating a favorable environment for advancements in drug discovery. The growing infrastructural development within the region, such as the establishment of research institutions and laboratories, has further supported the expansion of drug discovery activities, fueling the overall growth of cell-based assays within the region.
For more detailed information about the cell based assays market report, click here – https://www.databridgemarketresearch.com/reports/global-cell-based-assays-market
